Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia

Volume 22, Issue 6, June 2021, Pages 1921-1926

Erna Kristin; Dwi Endarti; Levina Chandra Khoe; Kartika Widayati Taroeno-Hariadi; Christina Trijayanti; Armansyah Armansyah; Sudigdo Sastroasmoro

• View Article
• PDF 372.88 K

Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab?

Volume 15, Issue 12, December 2014, Pages 4781-4786

• View Article
• PDF 514.42 K

Efficacy and Safety of Bevacizumab in Chinese Patients with Metastatic Colorectal Cancer

Volume 15, Issue 16, December 2014, Pages 6559-6564

• View Article
• PDF 837.85 K

XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology

Volume 15, Issue 23, December 2014, Pages 10375-10379

• View Article
• PDF 495.12 K

Pemetrexed is Mildly Active with Good Tolerability for Treatment of Patients with Colorectal Cancer

Volume 15, Issue 19, December 2014, Pages 8391-8394

• View Article
• PDF 348.9 K

Prognostic Factors for Overall Survival in Patients With Metastatic Colorectal Carcinoma Treated With Vascular Endothelial Growth Factor-Targeting Agents

Volume 13, Issue 3, March 2012, Pages 1059-1063

• View Article
• PDF 981.2 K